Publicacións en colaboración con investigadores/as de Centro Nacional de Microbiología (31)

2024

  1. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Determinants of poor clinical outcome in patients with influenza pneumonia: A systematic review and meta-analysis

    International Journal of Infectious Diseases, Vol. 131, pp. 173-179

2022

  1. Impact of previous macrolide use on invasive pneumococcal disease due to erythromycin-resistant serotypes in adults over 59 years of age

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 41, Núm. 2, pp. 227-234

  2. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

    The Lancet, Vol. 398, Núm. 10295, pp. 121-130

2019

  1. Identification of pneumococcal serotypes by PCR-restriction fragment length polymorphism

    Diagnostics, Vol. 9, Núm. 4

2016

  1. IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection

    Liver International, Vol. 36, Núm. 9, pp. 1258-1266

  2. Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients

    Journal of Translational Medicine, Vol. 14, Núm. 1

  3. Short communication: CXCL12 rs1029153 polymorphism is associated with the sustained virological response in HIV/Hepatitis C virus-coinfected patients on Hepatitis C Virus therapy

    AIDS Research and Human Retroviruses, Vol. 32, Núm. 3, pp. 226-231

2015

  1. TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients

    Journal of Clinical Virology, Vol. 65, pp. 62-67

  2. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  3. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Cunninghamella bertholletiae infection in children: Review and report of 2 cases with disseminated infection

    Journal of Pediatric Hematology/Oncology, Vol. 36, Núm. 2

  2. European mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients

    HIV Medicine, Vol. 15, Núm. 7, pp. 425-430

  3. PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy

    Journal of Acquired Immune Deficiency Syndromes, Vol. 67, Núm. 2, pp. 113-119

2013

  1. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients

    AIDS, Vol. 27, Núm. 2, pp. 163-173

  2. Chronic hepatitis e in HIV patients: Rapid progression to cirrhosis and response to oral ribavirin

    Clinical Infectious Diseases, Vol. 57, Núm. 3, pp. 465-468

  3. HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy

    AIDS, Vol. 27, Núm. 8, pp. 1231-1238

  4. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 20, Núm. 5, pp. 358-366